REMARKS

According to the Office Action, restriction of claims 2-27 to one of the following inventions is required under 35.U.S.C. 121:

I. Claims 2-11, 22, 26 and 27, drawn to a eukaryotic cell in vitro comprising a vector comprising a first promoter operably lined to a nucleotide sequence encoding a selectable marker, and a second promoter operably linked to an unpaired splice donor, wherein the vector is non-homologously integrated into the genome of said eukaryotic cell to express a fusion transcript comprising the nucleotide sequence encoding the selectable marker and/or the unpaired splice donor and one or more exons of an endogenous gene, and the coding sequence in said endogenous gene is translated, a library of said eukaryotic cell, and said vector, wherein the eukaryotic cell is an animal cell, a fungal or a yeast cell, classified in classes 435 and 424, subclasses 320.1 and 93.21, respectively.

II. Claims 12, 17, 21 and 23, drawn to a vector comprising a first promoter operably lined to a nucleotide sequence encoding a selectable marker, and a second promoter operably linked to an unpaired splice donor, said vector further comprising one or more transposition signals, a eukaryotic cell in vitro comprising said vector, and a library of said eukaryotic cell in vitro, classified in classes 435 and 424, subclasses 320.1 and 93.21, respectively.

III. Claims 13-15, 19, 21 and 23, drawn to a vector comprising a first promoter operably lined to a nucleotide sequence encoding a selectable marker, and a second promoter operably linked to an unpaired splice donor, said vector further comprising one or more viral origins of replication or viral replication factor genes, a eukaryotic cell in vitro comprising said vector, and a library of said eukaryotic cell in vitro, classified in classes 435 and 424, subclasses 320.1 and 93.21, respectively.

IV. Claims 16, 20, 21 and 23, drawn to a vector comprising a first promoter operably lined to a nucleotide sequence encoding a selectable marker, and a second promoter

operably linked to an unpaired splice donor, said vector further comprising genomic DNA, a eukaryotic cell in vitro comprising said vector, and a library of said eukaryotic cell in vitro, classified in classes 435 and 424, subclasses 320.1 and 93.21, respectively.

V. Claims 24 and 25, drawn to a method for increasing protein expression of an endogenous gene in a eukaryotic cell in vitro by introducing a vector into said eukaryotic cell, wherein said vector comprises a vector comprising a first promoter operably lined to a nucleotide sequence encoding a selectable marker, and a second promoter operably linked to an unpaired splice donor, wherein the vector is non-homologously integrated into the genome of said eukaryotic cell to express a fusion transcript comprising the nucleotide sequence encoding the selectable marker and/or the unpaired splice donor and one or more exons of an endogenous gene, and the coding sequence in said endogenous gene is translated, classified in class 435, subclass 69.1.

Accordingly, Applicants hereby elects Group I, claims 2-11, 22, 26 and 27 for examination *without traverse*.

Applicants reserve the right to traverse the restriction between the aforementioned groups in this or a continuing application. Applicants further reserve the right to pursue the non-elected groups in one or more divisional applications.

CONCLUSION

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned attorney at (617) 227-7400.

Dated: November 5, 2007

Respectfully submitted,

By /Cynthia L. Kanik
Cynthia L. Kanik, Ph.D.
Registration No.: 37,320
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant